Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada.
Adjuvant therapy has made a significant contribution in reducing breast cancer-specific mortality. Standard chemotherapeutics and tamoxifen have been the mainstay treatment for years, but recent clinical evidence supports the use of novel small-molecule therapy and aromatase inhibitor therapy in selected settings, challenging not only the traditional paradigm of breast cancer treatment, but also provincial funding of oncologic care across Canada. The disparity in access to aromatase inhibitor therapy for postmenopausal women with early-stage hormone-sensitive breast cancer across Canada is highlighted as an example.
Verma
S
S
Division of Medical Oncology, Toronto-Sunny-brook Regional Cancer Centre, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario. sunil.verma@sunnybrook.ca
Sehdev
S
S
Joy
A A
AA